Cajal Neuroscience integrates human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. Headquartered in Seattle, the company launched with the completion of a $96 million Series A financing. Its platform combines integrative human genetics and multi-omics, highly multiplexed functional genomics and industrialized whole-brain imaging to reveal mechanistic, spatial and temporal disease complexity. Cajal aims to systematically validate thousands of targets implicated in Parkinson’s, Alzheimer’s and other neurodegenerative diseases and to build foundational systems for target and drug discovery at scale. The leadership team and scientific co‑founders include experienced industry executives and leading neuroscientists such as Ignacio Muñoz-Sanjuán, Huda Zoghbi, Anthony Zador and Charles Zuker. The company plans to accelerate translation by applying sequencing, visualization and computational techniques to prioritize and advance therapeutic programs.

Total raised

$96M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2022